The specific purpose of this application is to obtain continued funding to support a multi-disciplinary program to conduct clinical research with cancer patients through participation in the Southwest Oncology Group (SWOG). This approach to cancer management is unique in this portion of the Pacific Northwest and provides contemporary treatment alternatives to an otherwise relatively isolated population. Specifically, the program proposes to: 1. Combine the disciplines of Surgical, Medical, and Radiation Oncology, Pathology, Immunology and Nursing Oncology in a synergistic attack on clinical cancer management by participation in SWOG protocols. 2. Participate in SWOG Phase II, III, and adjuvant studies. 3. Develop and conduct pre-clinical and clinical pilot studies for possible use by the SWOG. Such studies will include, but are not limited to, the neuroendocrine control of breast and prostatic cancer, regional chemotherapy by perfusion, infusion, and chemoembolization, suppression of functioning tumors of the gastrointestinal tract and other cancers by the synthetic somatostatin (Octreotide), multiple modality therapy in the treatment of tumors such as alveolar soft part sarcoma metastatic to lung, retroperitoneal sarcomas and mesothelioma of the pleura, and the genetics of hematopoietic growth factors. 4. Provide core laboratory support and suitable administrative facilities for the clinical evaluation of various techniques for the neuroendocrine control of cancer. 5. To modernize data entry and management capabilities by computerization as this capability develops within SWOG. 6. Further define chemosenstivity testing for determination of drug and hormone sensitivity in solid tumors. 7. To return SWOG information and expertise to the local area by consultation, lecture and symposia for the benefit of regional physicians and patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046113-10
Application #
2007673
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-01-01
Project End
1997-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
10
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Surgery
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404

Showing the most recent 10 out of 155 publications